Healthcare AI agents: what’s funding like now?

All funding deals in the healthcare AI agents market over the last 24 months

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our healthcare AI agents market report.

Is healthcare AI agent funding slowing down right now?

Healthcare AI agent startups raised less money and closed fewer rounds over the last 12 months.

We counted 100 deals compared with 112 deals in the 12 months before, and disclosed capital dropped to at least $2.5B from at least $2.9B. The number of funded companies barely moved, from 97 to 96, so investors still backed a similar range of startups. Investors are funding a similar number of businesses but writing fewer repeat checks within the period.

Big fundraises still happen. Forus's $125M Series B in May 2026 and $150M Series C in September 2026 address medication access, while Assort Health's $120M Series C in June 2026 addresses patient access, and Suki's $90M Series D+ in October 2026 backs automation for health-system workflows. These are separate opportunities to automate difficult healthcare processes, not interchangeable AI chatbots. The market is slower, but plenty of large healthcare automation bets are still happening.

Are $100M healthcare AI agent rounds becoming rare?

Healthcare AI agent startups still close nine-figure rounds, but the biggest checks are smaller than before.

The number of rounds above $100M declined from 6 to 4 deals, and those rounds raised $515M in the latest period against $1.2B previously. Forus's $150M Series C in September 2026 and $125M Series B in May 2026, Assort Health's $120M Series C in June 2026 and Candid Health's $120M Series D+ in July 2026 make up the high end of the newer period. In the earlier period, Abridge's $300M Series D+ in June 2025 helped set a different scale.

These companies are selling to different parts of a hospital or healthcare network. According to its September 2026 announcement, Forus aims to reduce the administrative barriers between prescriptions and treatment. Candid Health said in July 2026 that its system automates revenue-cycle work, while Abridge's June 2025 announcement emphasized documentation linked to reimbursement. Big checks still exist, but the largest one is smaller this time.

Is healthcare AI agent funding really falling without the giant rounds?

Without the biggest rounds, healthcare AI agent startups actually raised more money than before.

Funding excluding rounds above $50M reached at least $1.3B over the last 12 months, versus at least $1.2B in the 12 months before, an increase of 10%. Excluding rounds above $100M produced at least $1.9B against at least $1.7B, up 13%. Without the giant rounds, the funding comparison moves in the other direction.

The newer period contains meaningful funding well below the largest checks: Charta Health's $55M Series B in November 2026, Prosper AI's $30M Series A in June 2026 and Vitalize's $31M Series A in October 2026. Charta says it reviews medical charts before claims go out. Prosper describes agents connecting scheduling, insurance verification and billing. Vitalize targets hospital staffing. Investors are still backing software that completes difficult hospital tasks. The biggest slowdown was at the very top.

Are investors writing bigger checks for healthcare AI agents?

Healthcare AI agent startups are getting bigger typical checks even as total funding falls.

The median disclosed round rose 50%, to $15.0M over the last 12 months from $10.0M in the 12 months before. That is a more representative signal of check size than dividing the headline capital by the number of rounds. There were 40 deals from $5M to under $20M in the latest period and 22 deals from $20M to under $50M, compared with 45 and 20 deals respectively before. Deals under $5M fell from 30 to 19. The middle of the market held up while the smallest bracket weakened.

That does not make fundraising easier for every startup. A company that reaches Series A may still persuade investors to write a substantial check, while a founder attempting a smaller seed raise faces fewer comparable successes. Prosper AI's $30M Series A in June 2026 and Latent Health's $80M Series A in March 2026 both backed products designed to complete connected administrative tasks. Bigger successful checks can coexist with fewer new founders raising money.

Are fewer healthcare AI agent startups getting backed?

Hardly fewer healthcare AI agent startups raised money, but far fewer closed multiple rounds in the same period.

Our count moved from 97 funded companies in the preceding 12 months to 96 over the last 12 months. What changed more sharply was repeat funding within each period: 15 companies raised more than once before, versus 4 companies most recently. The repeat rate fell from 15% to 4%. That combination explains how funded-company breadth can look steady even when total deal activity falls.

Most financed startups are still distinct companies, with different customers and products. Assort Health, Candid Health and Forus each have a distinct product and financing story. Meanwhile, some startups such as Forus and TJM Labs appear in more than one financing within the latest window. Repeat closings became less common, even though established companies kept raising money.

Can a new healthcare AI agent startup still raise money?

New healthcare AI agent startups can still get their first check, but fewer are managing it.

We recorded 23 first-financing deals worth $166M in the last 12 months, compared with 33 deals and $223M in the 12 months before. The share of deals classified as first financings moved from 29% to 23%, while follow-on rounds captured a larger portion of the market. We call a round a first financing only when the source says so, and a follow-on only when an earlier equity round is in our records, so about a fifth of deals in each period stay unclassified.

New entrants still appear in different parts of the workflow. Ferry Health's $9M Seed in September 2026 targets appointment navigation. Uncovr's $7M Seed in June 2026 aims to automate surgical video documentation and coding. Shyld AI's $13M Seed in May 2026 targets healthcare operations. Those deals show new ideas still get through. But fewer first-time fundraises closed than before.

Are investors favoring established healthcare AI agent startups?

Investors now put a larger share of healthcare AI agent funding into startups that have already raised.

Follow-ons made up 57% of deals in the latest 12 months, up from 48% in the previous 12 months, and accounted for 82% of disclosed capital. The earlier period had also been dominated by follow-on money, with 84% of disclosed capital, so the change is more visible in the mix of deals than in the capital share alone. We recorded 57 follow-on rounds most recently versus 54 earlier, and 20 deals in the latest period have no confirmed status.

Company announcements help explain why investors keep returning to existing products, though they do not reveal every investment decision. Candid Health said its $120M Series D+ in July 2026 followed rapid contracted revenue growth. Assort Health's July 2026 company update described a broader platform spanning calls, scheduling, referrals and payments. Established systems can show customers what workflows are actually completed. Customers can test finished work more easily than a startup pitch.

Are investors backing away from seed-stage healthcare AI agents?

Healthcare AI agent seed funding has dropped sharply, even as Series A deals have grown.

Seed fell to 34 deals and at least $232M in the latest 12 months from 57 deals and at least $294M in the preceding period. Its deal share dropped from 51% to 34%. It is a material reduction in the number of recorded early financings.

The sector still has young teams attacking specific tasks. InTouchNow's approximately $3.1M Seed in September 2026 backs phone agents for general practitioners, and Kairon Health's $5M Seed the same month backs engagement and care coordination. But healthcare buyers need systems that can access records, respect permissions and finish work inside operational processes. Epic's September 2026 account of hospital-built agents illustrates how closely these systems must fit actual care teams. Seed activity is down. We cannot pin that decline on compliance or long sales cycles without stronger evidence.

Are more healthcare AI agent startups raising Series A?

More healthcare AI agent startups are closing Series A rounds now than in the preceding period.

We recorded 40 Series A deals worth $809M in the latest 12 months, versus 33 deals worth $667M in the preceding period. Series A therefore represented 40% of all recent deals, compared with 29% previously. Seed remains important, but the market now funds considerably more startups at the next named stage than it did before.

Some of those Series A checks are unusually large. Latent Health's $80M Series A in March 2026 backed a platform that coordinates medication access. Prosper AI's $30M Series A in June 2026 backed a connected patient journey. Vitalize's $31M Series A in October 2026 targeted hospital staffing. Their financing announcements describe several actions integrated into a workflow rather than a stand-alone prediction or text generation tool. More startups are raising Series A, while fewer get seed checks.

The table below shows the deal counts and capital by stage.

Stage	Last 12m deals	Prior 12m deals	Last 12m capital
Series A	40	33	$809M
Series B	13	5	$683M
Series C	4	9	$410M
Seed	34	57	$232M+
Series D+	2	4	$210M
Growth Equity	2	1	$70M
Unknown	5	3	$41M+

Why are fewer healthcare AI agent startups reaching Series C?

Healthcare AI agent startups have secured more Series B rounds but far fewer Series C and Series D+ rounds.

We tracked 13 Series B deals and $683M in the latest 12 months, compared with 5 deals and $347M earlier. But Series C declined to 4 deals from 9, and Series D+ declined to 2 deals from 4. There is more activity at Series B, but fewer startups are closing the largest, later-stage rounds.

Suki's $90M Series D+ in October 2026 shows that later-stage money still exists for businesses expanding beyond notes. Suki's own October announcement described new clinical reasoning, revenue-cycle and operational capabilities. Candid Health's $120M Series D+ in July 2026 represents a different use for mature capital: the flow from medical service to paid claim. Far fewer startups make it past Series B.

Are AI medical scribes losing their funding lead?

AI medical scribes have lost much of their old lead in healthcare-agent fundraising.

The category declined from 27 deals and $1.2B in the preceding 12 months to 12 deals and at least $419M most recently. Its share of deals fell from 24% to 12%. Much of the earlier funding came from Abridge's $300M Series D+ in June 2025 and Ambience Healthcare's $243M Series C in July 2025, two rounds supporting documentation products that connect medical notes with broader clinical and administrative work.

Clinical documentation continues to attract major rounds. Heidi Health's $100M Series C in September 2026 and Tandem Health's $100M Series B in September 2026 demonstrate serious investment outside the United States. Heidi's public financing announcement also distinguished its equity round from a separate growth investment, an important reason not to merge every announced dollar into venture equity totals.

The table below shows category financings in the two consecutive periods.

Category	Last 12m deals	Prior 12m deals	Last 12m capital	Prior 12m capital
Revenue Cycle Agents	19	17	$472M+	$243M
Provider Operations Agents	23	27	$446M+	$473M
Prior Authorization Agents	8	8	$446M	$181M
Clinical Documentation Agents	12	27	$419M+	$1.2B
Patient Access & Scheduling Agents	16	11	$262M	$150M
Care Coordination Agents	12	12	$229M	$238M
Patient Communication & Navigation Agents	10	10	$181M	$373M+

Is AI billing automation becoming a bigger funding target than scribes?

AI billing startups are attracting more healthcare-agent funding while documentation loses ground.

We counted 19 revenue-cycle deals and at least $472M in the latest 12 months, compared with 17 deals and $243M in the preceding period. Their share of disclosed capital increased from 8% to 19%. That is meaningful growth both in deal count and dollars, even while the entire market's headline funding softened.

Candid Health's $120M Series D+ in July 2026 automates the claims and reimbursement process. Charta Health's $55M Series B in November 2026 focuses on checking the underlying charts before claims go out. TJM Labs' $75M Series B in July 2026 automates pharmacy workflows, showing how connected financial and operational tasks can overlap. Investors can see a concrete customer expense being addressed. But categories are different companies, and funding announcements do not identify which rejected deals or portfolio allocations financed the shift. We can see billing deals growing. We cannot prove which investors stopped backing scribes to fund them.

Is AI prior authorization attracting serious venture funding?

AI prior authorization startups are getting much bigger checks with the same number of deals.

Over the last 12 months, prior authorization agents had 8 deals worth $446M, compared with 8 deals worth $181M previously. Their share of disclosed capital rose from 6% to 18%, while deal share moved only from 7% to 8%. Forus's $125M Series B in May 2026 and $150M Series C in September 2026, along with Latent Health's $80M Series A in March 2026, show how heavily the category depends on a few large rounds.

Federal policy may add urgency, but it does not prove why any investor wrote a check. CMS's January 2024 prior-authorization final rule set new operational obligations beginning in 2026 and API requirements generally beginning in 2027, with exceptions and exclusions. Those changes make electronic exchange and authorization administration prominent problems for payers and providers. They do not make autonomous decisions clinically acceptable by default. Investors will back tools that reduce the paperwork, but the numbers say nothing about whether unattended clinical decisions are safe.

Are patient-scheduling AI agents catching up with note-taking tools?

Patient-scheduling AI agents are attracting more investment as clinical documentation funding cools.

Patient access and scheduling recorded 16 deals worth $262M in the latest period, compared with 11 deals and $150M before. Its share of deals increased from 10% to 16%. The move is especially visible in companies selling software that does something after answering a call: it schedules appointments, checks insurance, or routes a referral rather than stopping at conversation.

Assort Health's $120M Series C in June 2026 backs an expanded patient-access platform. Prosper AI's $30M Series A that month describes a connected process from appointment booking through billing. Startups want to handle what happens after a patient calls, from booking to billing, while Epic builds overlapping tools inside records software.

Are investors overlooking AI care coordination?

AI care coordination startups are still being funded, but their deal count has not grown.

There were 12 care-coordination deals and $229M in the latest 12 months, versus 12 deals and $238M in the preceding 12 months. Those counts are identical, while disclosed capital differs. Companies still target handoffs across care teams, but there is no rush of new deals comparable to patient access.

Examples span several forms of coordination. Thesis Care's $45M Series A in March 2026 backs AI-powered clinical care teams, while Basalt Health's $20M Series A in September 2026 targets post-acute admissions and Kairon Health's $5M Seed in September 2026 targets patient engagement. Each requires connections to real clinical workflows rather than merely returning advice. Care coordination has not lost its place, but funding has barely moved while patient access has grown.

Is healthcare AI agent funding still mostly American?

Healthcare AI agents are attracting more funding deals outside the United States, though US startups still raise most of the money.

American companies accounted for 71 deals in the latest 12 months, versus 87 in the preceding period. Their deal share fell from 78% to 71%. Europe moved from 13 to 19 deals, and Latin America moved from 2 to 5 deals. The United States still dominates, with 81% of disclosed capital in the newer period.

Heidi Health's $100M Series C in September 2026 in Australia and Tandem Health's $100M Series B in September 2026 in Sweden illustrate how non-U.S. developers can win sizeable backing. France also produced Vocca's $20M Series A in October 2026 for healthcare voice agents. More non-US startups are finding investors even as global funding cools. These are headquarters locations, not statements about where customers, engineers or investors reside.

Are fewer investors leading healthcare AI agent rounds?

Fewer firms are leading healthcare AI agent rounds than in the preceding period.

We identified 82 distinct lead investors in the latest 12 months, down from 111 in the previous period. Lead investors were disclosed on 88% of deals in both periods, so missing names cannot explain most of the decline. The total count of unique investors also fell from 158 to 121.

Andreessen Horowitz remained the most active disclosed lead in the latest period, leading 5 rounds, while Oak HC/FT and Flare Capital Partners each led 3 rounds. Those are counts of rounds led, not the investors' personal contributions. Fewer active lead investors leave founders with a shorter list of firms that have recently written checks. But we can't see rejected pitches, or investors who would have invested at another price. Fewer investors actually led completed rounds.

Are healthcare AI agent startups waiting longer between funding rounds?

Healthcare AI agent startups with repeat rounds are now waiting longer between financings.

The median observed interval increased from 10.5 months in the preceding 12-month window to 18 months most recently. The share of measured gaps shorter than 12 months fell from 55% to 30%, and the share shorter than 18 months moved from 80% to 44%. These are shares of gaps between financings by the same company, not shares of all companies.

The measure is based on a subset: the underlying round-history coverage is 57% for the latest period and 50% for the earlier one. This measure works best for startups with well-documented round histories. Nevertheless, the direction is consistent with fewer within-period repeat financings. This will not predict every startup’s runway, but it makes a quick follow-on round a risky assumption.

Do healthcare AI agent startups need to be older to raise?

Older healthcare AI agent startups are not automatically getting the biggest checks.

The median company age at funding rose from 2 years to 3 years across the two 12-month periods. Yet among companies receiving rounds above $50M, median age fell from 6 years to 3 years. Being older clearly does not guarantee a bigger check.

Forus, Assort Health and Latent Health each address a specific administrative problem. Their age tells us little about customer traction or profitability. Forus described a medicine-access network after its $150M Series C in September 2026, Assort detailed its expanding patient-access workflows in July 2026, and Latent said in March 2026 that it worked with major health systems on medication access. Their product claims help explain why investors backed young companies, but three cases don't make a rule for the whole market.

Are healthcare AI agents already doing real work in hospitals?

Healthcare AI agent companies are increasingly offering tools that complete real hospital tasks, although adoption varies.

Suki said in October 2026 that its platform was extending from clinical notes into reasoning, revenue-cycle and operational workflows. Prosper AI said in June 2026 that its agents connected scheduling, verification and billing. Charta Health described chart review before claims submission in November 2026. Those are tangible tasks with defined handoffs and human approval points.

Epic said in September 2026 that teams from 25 health systems used its Agent Factory to build task-completing agents. Its examples included transfer requests and medication-refill checks. That shows healthcare buyers can access automation without always purchasing a new independent platform. Our funding figures prove investor activity. They do not independently verify revenue, error rates, clinical safety or deployment scale across the whole market. Competition has moved toward agents that complete work inside existing healthcare software.

Can Epic squeeze independent healthcare AI agent startups?

Epic can compete directly with independent healthcare AI agent startups by building similar tools into its record software.

Epic's September 2026 Agent Factory announcement described health systems building their own agents inside the health-record environment. Its August 2026 prior-authorization work likewise pointed to administrative checks embedded directly in clinical software. Those tools compete for some of the same buyer budgets as independent startups, especially where the problem is a narrow feature inside an existing workflow.

Independent startups still have ways to win. Assort Health connects conversations, referrals and scheduling. Latent Health targets medication-access steps across organizations. And Candid Health focuses on revenue-cycle automation. Their task is to show that a specialized system is better integrated, more dependable or easier to operate than a built-in alternative. We cannot blame Epic for the funding slowdown. Independent startups do have to compete with tools hospitals can now build into software they already use.

So, what does healthcare AI agents funding look like right now?

Healthcare AI agents funding has cooled, but startups that complete costly hospital workflows can still raise serious money.

The headline trend is weaker, with fewer rounds and less capital than in the preceding 12 months. On the bright side, the typical check got bigger, and so did the money outside the largest rounds. Seed and first financings became less common, while more of the recorded deals were Series A or follow-on rounds. Forus led the recent period by money raised, with $275M across its May 2026 Series B and September 2026 Series C. Andreessen Horowitz remained the busiest lead investor in that period.

Investors are now making more selective healthcare-agent bets. Healthcare organizations are still buying and building tools that complete tasks, and the financing is moving toward those practical applications. What is missing is a stronger flow of first checks for new founders.

The table below shows what we found.

Question	Answer
Is the entire healthcare-agent boom still accelerating?	No, total healthcare-agent financing has slowed over the latest comparison period. Disclosed capital fell 15% despite several large rounds still closing. Smaller deals actually held up better than the overall total suggests.
Did large checks disappear from healthcare automation?	Large healthcare-agent rounds still happen, but fewer now reach nine figures. Forus closed two of them in 2026, including a $150M Series C in September. That does not restore the previous period’s stronger high end.
Did the everyday funding market shrink too?	Ordinary healthcare-agent funding grew once we removed the very biggest deals. Capital excluding rounds above $50M rose 10% between comparable periods. Giant rounds explain much of the decline seen in total funding.
Are investors writing smaller healthcare software checks?	The typical healthcare-agent round has grown even as total funding fell. Median disclosed financing reached $15M in the latest period. A drop in smaller seed deals helped push that median higher.
Did fewer independent companies find an investor?	The number of funded healthcare-agent companies has barely moved this period. We tracked 96 funded companies across the latest 12 months. Fewer completed repeat rounds explain part of the falling deal count.
Is a first outside check still routine?	First checks for healthcare-agent startups have become much harder to find. First financings represented 23% of deals during the latest period. Existing funded startups are taking a larger share of completed rounds.
Is the seed-stage pipeline as active today?	Seed is now the weak point in healthcare-agent venture funding. Only 34 seed rounds closed over the latest 12 months. Series A deals now make up a larger part of activity.
Are clinical note makers still absorbing everything?	Medical note-makers no longer take the lion’s share of new rounds. Clinical documentation recorded 12 deals across the latest 12 months. Billing and hospital operations are attracting bigger pieces of investment.
Did billing automation gain real investor support?	AI billing companies are drawing larger commitments from healthcare venture investors. Revenue-cycle agents raised at least $472M over the latest period. Their products tackle coding, claims and the work needed for payment.
Does the United States still control financing?	American companies still dominate healthcare-agent fundraising despite growing overseas activity. US startups attracted 81% of recently disclosed capital. Europe is gaining deals, but not matching American funding totals.
Can startups still expect rapid repeat rounds?	Quick follow-on rounds have become less common for healthcare-agent startups. The median measured gap reached 18 months in the latest period. Founders should plan for a longer wait, not an automatic repeat raise.